Is IMDX or MYGN more undervalued in 2026?

CirclFi compares Insight Molecular Diagnostics I (IMDX) and Myriad Genetics, Inc. (MYGN) using 13 institutional-grade valuation models. IMDX has a Quality of Company score of 5.3/10 while MYGN scores 6.6/10.

Which is a better buy — IMDX or MYGN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IMDX and MYGN valuations compare?

IMDX at $6.21 and MYGN at $3.97 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IMDX vs MYGN Valuation Comparison 2026 — Intrinsic Value Analysis

IMDX

In Vitro & In Vivo Diagnostic Substances

Insight Molecular Diagnostics I

Quality

5.3

out of 10

Value Trap

SAFE

Price

$6.21

Last close

Models

10/13

Active

MYGN

In Vitro & In Vivo Diagnostic Substances

Myriad Genetics, Inc.

Quality

6.6

out of 10

Value Trap

SAFE

Price

$3.97

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	IMDX Fair Value	IMDX Upside	MYGN Fair Value	MYGN Upside
Bayesian DCF	Intrinsic	$2.00	-67.9%	$0.08	-98.1%
Earnings Power Value	Intrinsic	$1.19	-71.6%	$16.62	+318.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMDX vs MYGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMDX vs MYGN — Which Stock Is More Undervalued?

MYGN scores higher with a 6.6/10 quality rating vs IMDX's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Insight Molecular Diagnostics I (IMDX) and Myriad Genetics, Inc. (MYGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMDX currently trades at $6.21 with a QOC of 5.3/10, while MYGN trades at $3.97 with a QOC of 6.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).